Medicare soon will start something it hasn't done in its 58-year history: Negotiate on drug prices. On Sept. 1, Medicare will target the first 10 drugs for price negotiations.
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients. Here's what the fuss is all about.
The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.
Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.
Medicare suddenly stopped paying for the pricey drug that prolongs his life. As he waits for an appeal, this retired physician wonders if he should give up treatment to spare his family the cost.
The Inflation Reduction Act gives Medicare historic new powers to limit prescription drug prices. But the pharmaceutical industry is already lobbying to dull their impact.
New legislation that aims to lower the cost of some brand name prescription drugs for insured patients would increase transparency in medication pricing for Georgians.
The move comes just days before a U.S. rule was set to go into effect allowing for bulk importation of drugs from Canada. Trump promised it would lower costs and be a "game changer" for seniors.
